Correlation between the Lymphocytic Infiltration of Tumors and the Proliferative Activity of Cancer Cells from Surgically Treated Esophageal CarcinomaIkeguchi M. · Saito H. · Katano K. · Tsujitani S. · Maeta M. · Kaibara N.
Department of Surgery I, Faculty of Medicine, Tottori University, Yonago, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
To evaluate the correlation among the biological behavior of cancer cells, the local immune response of the host, and survival of patients with esophageal carcinoma, we investigated the proliferative activity of cancer cells by immunostaining with the Ki-67 monoclonal antibody in 95 cases of surgically resected esophageal squamous cell carcinoma and compared them with the extent of lymphocytic infiltration of the tumor (LI) in the same specimens. The mean Ki-67 score of 43 tumors with low-grade LI was 46.7% and it was not different from that of 52 tumors with high-grade LI (49.4%, p = 0.441). A significant correlation between the Ki-67 score and the clinicopathological characteristics of tumors (depth of tumor invasion, lymph node metastasis, and stage) was detected. However, in the same stage, the survival of patients with a low Ki-67 score was not different from that ofpatients with a high Ki-67 score. On the other hand, even no significant correlation between the extent of LI and the clinicopathological characteristics of tumors was found; the 5-year survival rate of 17 patients with high-grade LI (13.9%) was significantly better than that of 15 patients with low-grade LI (0%, p = 0.07) in stage III. These facts indicate that proliferative activity might correlate with the tumor progression, however, when the survival is compared in the same stage, the local immune response such as the extent of lymphocytic infiltration of the tumor might be the better prognostic factor than proliferative activity in patients with esophageal cancer.
© 1997 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.